Among the various novel prognostic models that contain numerous promising biomarkers, including those of cellular origin (such as germinal centre B cell and activated B cell types) and immunoexpression patterns (including p53, Ki67, Bcl-2, Bcl-6, CD10 and CD5), none has achieved the required level of acceptance to be routinely used for risk stratification of DLBCL patients (12–16). This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.